Recently, Sheng et al. reported that either knocking out or pharmacologically inhibiting LSD1 in a mouse model of melanoma overcame the tumor's resistance to anti-PD-1 therapy by increasing tumor immunogenicity and T cell infiltration, suggesting that combining LSD1 inhibition with PD-1 and/or PD-L1 blockers might serve as an effective strategy for treating certain types of cancer [50]. The gene discussed is CD274; the disease is neoplasm.